45 results about "APOPTOGENIC PROTEIN" patented technology

The invention discloses lactobacillus plantarum DP189 and application thereof, and relates to the field of functional food microorganisms. The strain is preserved in China Center for Type Culture Collection on March 25 , 2019 with the preservation number of CCTCC NO:M2019199. By means of the strain, the learning and memory capability of a depressed rat can be improved; the level of brain-derived neurotrophic factors of the depressed rat can be improved; the injury to hippocampal neurons and apoptosis of neuron cells of the depressed rat are reduced; the content of apoptosis proteins JUK2 and Bcl-2 of brain tissue of the depressed rat is lowered; the abundance of verrucomicrobiaceae of the intestinal tract is lowered; the abundance of bacterium lacticum of the intestinal tract is improved, the alpha-diversity of the intestinal floras is improved, and the intestinal flora disturbance of the depressed rat is alleviated. In this way, the lactobacillus plantarum DP189 has good effects of preventing and treating depression / anxiety, infantile autism and inflammatory enteritis. The strain has the anti-depression function, and can serve as a functional probiotic bacterium for preventingand treating the depression, infantile autism and inflammatory enteritis, and a new idea is provided for clinical intervention with and control over depression and other relevant mental diseases.

Disclosed are compounds of formula (I) which inhibit the activity of anti-apoptotic Bcl-xL proteins, compositions containing the compounds and methods of treating diseases during which Bcl-xL proteins are expressed, eg cancer. X is heteroaryl; Y1 is phenylene or heteroarylene; L1 is a linker; Y2 is cycloalkyi, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl; Z1 is C(O)OR9, C(O)NR10R11, C(O)R11, NR10C(O)R11, etc.

The invention discloses a novel BH3 analogue targeted to Bcl-2 family anti-apoptotic protein and application of the novel BH3 analogue. The structural general formula of the BH3 analogue is as shown in the general formula A (the general formula A can be found in specification). A thought and method of peptidomimetics is adopted, the structure of a natural BH3 peptide fragment is simplified or modified, and the novel BH3 analogue is obtained. It is proved by experiments that the compound as shown in the general formula A and the Bcl-2 family anti-apoptotic protein represent excellent binding activity on the aspect of the molecular level; and it is shown by in-vitro carcinoma cell growth inhibition experiments that the compound has a certain in-vitro growth inhibition function on the human chronic myeloid leukemia cell K562, the human promyelocytic lenukemia cell HL-60 and the human tissue cell lymphoma cell U937. It is prompted by research results that the compound can be used as a candidate drug for preventing or treating related diseases caused by expression abnormality of anti-apoptotic protein in the Bcl-2 family protein.

The invention belongs to the biotechnical field, and concretely relates to a tumor necrosis factor family cell apoptosis protein fusion protein, and a preparation method and a use thereof. The fusion protein is composed of annexin, a connecting peptide and a tumor necrosis factor family cell apoptosis protein, and coding gene of the fusion protein is constructed through cloning. The tumor necrosis factor family cell apoptosis protein fusion protein has a substantial enhanced cell apoptosis induction effect, can induce the apoptosis of tumor cells insensitive to the cell apoptosis, and can reduce the protein administration dosage needed by the obtaining of the treatment effect.

The present invention relates to HGyV, a human gyrovirus related to the chicken anemia virus (CAV). The present invention also relates to a new proteins encoded by HGyV, which proteins display some homology to CAV proteins. Among these new proteins, H-apoptin is of particular interest as it is herein found for the first time in a human virus and can be used for treating cancer. Also provided are methods for detecting the HGyV virus in a subject.

The invention discloses a new method for diagnosing and reversing drug resistance of tumor cells to etoposide (also known as VP-16 and vepeside) by revealing a mechanism that the tumor cells generate drug resistance to a chemotherapy drug namely the etoposide. By detecting expressions of miRNA and apoptosis-related proteins in the tumor cells with different sensitivities to the etoposide, the inventor discovers that miR-17-5p and miR-20a show low expression in the cells with high sensitivities to the etoposide, but garget gene Bim-S pro-apoptotic proteins of the miR-17-5p and miR-20a show high expression. On the contrary, in the cells with drug resistance to the etoposide, the expression quantities of the miR-17-5p and miR-20a are high, but the Bim-S proteins show low expression. An inhibitor using the miR-17-5p and / or miR-20a can be used for effectively reversing the drug resistance of the tumor cells to the etoposide. The invention provides a brand-new simple and effective method for detection and / or prognosis of drug resistance of cancers to the etoposide, and provides a means of reversing the drug resistance of the tumor cells, which has great potential application values in clinical diagnosis and personalized treatment of tumors.

The invention discloses 432 novel acetylation sites identified in signal transduction proteins and pathways underlying human protein acetylation signaling pathways, and provides acetylation-site specific antibodies and heavy-isotope labeled peptides (AQUA peptides) for the selective detection and quantification of these acetylated sites / proteins, as well as methods of using the reagents for such purpose. Among the acetylation sites identified are sites occurring in the following protein types: Acetyltransferases, Adaptor / Scaffold proteins, Actin binding proteins, Adhesion proteins, Apoptosis proteins, Calcium-binding proteins, Cell Cycle Regulation proteins, Cell Surface proteins, DNA binding proteins, DNA replication proteins, Channel proteins, Chaperone proteins, Cellular Metabolism enzymes, Cytoskeletal proteins, DNA repair proteins, Endoplasmic reticulum proteins, Enzyme proteins, G protein and GTPase Activating proteins, Guanine Nucleotide Exchange Factors, Helicase proteins, Isomerase proteins, Extracelluar matrix proteins, Hydrolases, Ligase proteins, Lipid kinases, Inhibtor proteins, Lipid Binding proteins and Lyases.

The invention provides an icariside I compound and a derivative and a pharmaceutical salt. A structure formula is shown as a formula I in the description. The compound, the derivative, the pharmaceutical salt or the composite is used for preparing medicine capable of being used for preventing, relieving or treating tumor diseases. The tumor includes liver cancer, lung cancer, colon cancer, ovariancancer, bile duct cancer, malignant lymphoma, liver cancer, bladder cancer and prostate cancer. The icariside I compound has obvious effects in aspects of improving the human immunity, improving thehuman IFN-gamma level, improving the apoptin NOXA expression and the like. Through in vivo experiments on mice and liver cancer cells (H22 cells and hepg2 cells) experiments, the results prove that the icariside I can obviously inhibit the tumor growth.

The invention discloses nearly 443 novel phosphorylation sites identified in signal transduction proteins and pathways underlying human carcinoma, and provides phosphorylation-site specific antibodies and heavy-isotope labeled peptides (AQUA peptides) for the selective detection and quantification of these phosphorylated sites / proteins, as well as methods of using the reagents for such purpose. Among the phosphorylation sites identified are sites occurring in the following protein types: Protein kinases (including Serine / Threonine dual specificity, and Tyrosine kinases), Adaptor / Scaffold proteins, Transcription factors, Phospoatases, Tumor supressors, Ubiquitin conjugating system proteins, Translation initiation complex proteins, RNA binding proteins, Apoptosis proteins, Adhesion proteins, G protein regulators / GTPase activating protein / Guanine nucleotide exchange factor proteins, and DNA binding / replication / repair proteins, as well as other protein types.

The invention relates to use of Ruxolitinib in preparation of a drug for treating M2 type acute myeloid leukemia with t (8; 21) chromosome translocation, and the in-vitro effective concentration is 1 * 10<-6>-1 *10<-5>M. Drug Ruxolitinib is not only itself has the effect of inhibiting growth and inducing apoptosis on leukemia cell Kasumi-1, and enhances the drug sensitivity of the leukemia cell Kasumi-1 on rsTRAI by up-regulation of mRNA and protein expression level of DR4, up-regulation of cell apoptosis protein Bax expression, activation of apoptosis protein caspase-3 and inhibition of NF-kappa B protein activity. The drug can be used for treating the M2 type acute myeloid leukemia with t (8; 21) chromosome translocation, the new drug for treating the M2 type acute myeloid leukemia with t (8; 21) chromosome translocation is provided, and a new approach for overcoming TRAIL resistance in leukemia cells can be provided.

The invention uses lycium ruthenicum as a raw material to extract a polysaccharide, and uses an anthrone-ethyl acetate-concentrated sulfuric acid solution to determine the content of the polysaccharide. The fruits of lycium ruthenicum are subjected to crushing, soaking, heating, filtering, suction filtration and other treatment to obtain a solution containing the lycium ruthenicum polysaccharide;the extracted lycium ruthenicum polysaccharide is subjected to water extraction and alcohol precipitation, and suction filtration, a filter cake is oven-dried in an oven, a polysaccharide powder is taken out, DMSO is added for dissolution, stirring is performed for 12 h under a magnetic stirrer, distilled water is added, and suction filtration is performed; a precipitate is washed with anhydrous ethanol, acetone, and diethyl ether in order, and drying is performed to obtain a lycium ruthenicum polysaccharide refined product; and the lycium ruthenicum polysaccharide refined product is subjectedto macro-porous resin decolorization and Sevage method deproteinization to obtain the lycium ruthenicum polysaccharide. The yield of the polysaccharide is greatly improved by using the DMSO method for refining, the lycium ruthenicum polysaccharide is applied to K562 cells, cell apoptosis can be promoted by changing an expression amount of relevant apoptotic proteins in the mitochondrial pathway,and the lycium ruthenicum polysaccharide has the anti-leukemia tumor effect.

The invention relates to the technical field of life beauty, and discloses a mole removing paste which is prepared from the following raw materials by weight: 0.25 milligram of radix sophorae flavescentis, 0.25 gram of golden cypress, 0.15 milligram of gallnut, 0.15 milligram of honeycomb and 0.2 milligram of borneol. The raw materials are uniformly mixed, and CAS apoptosis protease is extracted. When in use, the product can quickly decompose and soften cutin and decompose melanin, so that the mole scabs and falls off along with metabolism of a human body, and no scar is left.

The invention belongs to the technical field of cytobiology, relates to a method for inducing apoptosis by thermal stimulation, and in particular to a method for inducing apoptosis by taking a PCR temperature control system as thermal stimulation. According to the method, a gradient gradual heating mode is adopted, wherein gradient gradual heating means the temperature stays for a period of time after rising; and the temperature is gradually reduced in a gradient manner after rising to a target temperature and being kept for a period of time. A model for inducing apoptosis based on a gradientgradual heating mode of a PCR precise temperature control system is established, so that the early apoptosis rate of the method is more than than the sum of the late apoptosis rate and the necrosis rate, and the method has good reproducibility and stability. The effect verification on drugs and the detection on related apoptotic proteins can be achieved due to the high early apoptosis rate; Apoptosis caused by the thermal stimulation method can be used for simulating fever of an organism caused by various reasons (pathogenic microorganism infection, organism inflammatory response, malignant tumor diseases and the like), and thermal stimulation caused by the fever can cause damage to myocardial cells and the like of the organism.

The invention discloses an apoptotic protein fusion type anti-HER-2 single-chain antibody as well as a preparation method and application thereof. The apoptotic protein fusion type anti-HER-2 single-chain antibody is formed by coupling an anti-HER2 single-chain antibody with apoptotic protein in different series modes, and the apoptotic protein is a cytochrome C or DNA fragmentation factor 40, canbe specifically coupled with the anti-HER-2 single-chain antibody to form a DFF40-scFv fusion type single-chain antibody and an nCytc (series)-scFv fusion type single-chain antibody. The apoptotic protein fusion type anti-HER-2 single-chain antibody is inserted into the upstream of scFv through a cDNA sequence of the apoptotic protein and cloned into an expression vector to construct recombinantplasmids, the recombinant plasmids are transferred into cells to induce expression of the apoptotic protein fusion type anti-HER-2 single-chain antibody, the preparation method is easy to construct and express, the constructed apoptotic protein fusion type anti-HER-2 single-chain antibody can specifically target HER-2 high-expression malignant tumors and mediate cancer cell apoptosis, and can be used for preparing drugs for targeted therapy of HER-2 high-expression cancers.

The invention discloses preparation of a compound of Au and an anti-apoptotic protein antagonistic peptide and application of the compound in synergistic induction of tumor cell apoptosis, and relates to the field of anti-tumor drugs. Mixing a gold salt solution with the anti-apoptotic protein antagonistic peptide containing sulfydryl; under the conditions of certain temperature and pH, redox reaction is carried out, high-valence Au ions are reduced into Au atoms or monovalent Au ions, and Au acts on sulfydryl of polypeptide to form a compound AuP; the sulfydryl-containing anti-apoptotic protein antagonistic peptide is selected from polypeptides with an intracellular anti-apoptotic protein antagonistic function. The AuP compound has broad-spectrum anti-tumor activity, and compared with a common peptide-gold compound or gold compound, the AuP compound can inhibit the activity of thioredoxin reductase and antagonize the function of high-expression anti-apoptotic protein at the same time, the single-drug double-target synergistic effect is achieved, and the curative effect is remarkably improved. The compound can be used for treating various malignant tumors such as chronic lymphocytic leukemia, acute monocytic leukemia and non-Hodgkin lymphoma.

The invention relates to methods for predicting the clinical outcome of cancer patients, and in particular of acute lymphoblastic leukaemia (ALL) patients, in response to a therapy against ALL, preferably conventional chemotherapy, more preferably based on glucocorticoids, said methods based on the presence of particular polymorphism in genes coding for drug-metabolizing enzymes and apoptotic proteins. The invention relates as well to method for predicting the efficacy of a therapy based on conventional glucocorticoids as well as to method for personalized medicine in patients carrying said polymorphisms.

The invention belongs to the field of biological technology, and specifically discloses a tumor necrosis factor family cell apoptosis protein fusion protein, a preparation method and application thereof. The fusion protein is composed of annexin, connecting peptide and tumor necrosis factor family cell apoptosis protein, and the coding gene of the fusion protein is constructed by cloning. The tumor necrosis factor family cell apoptosis protein fusion protein has significantly enhanced effect of inducing apoptosis, can induce apoptosis of tumor cells insensitive to cell apoptosis, and can reduce protein dosage required for obtaining therapeutic effect.

The invention discloses application of tartary buckwheat flavone in preparation of a medicine for treating pancreatic cancer, and finds that the tartary buckwheat flavone can obviously promote apoptosis of pancreatic cancer cells, inhibit proliferation of the pancreatic cancer cells and break DNA (deoxyribonucleic acid) in the aspect of researching the activity effect of the tartary buckwheat flavone on the pancreatic cancer cells, and has huge potential in the aspect of exerting tumor resistance. The tartary buckwheat flavone is prepared from tartary buckwheat powder through alcohol extraction and resin purification, the preparation method is simple, when the tartary buckwheat flavone is used for preparing the medicine composition for preventing, treating or improving pancreatic tumors, the tartary buckwheat flavones can promote the expression of apoptosis protein Caspase-3, Caspase-8, Cleave-Caspase-3, Cleave-Casspse8, Cleave-caspase9 and Bax and inhibit expression of anti-apoptosis protein Bcl-2, it is proved that the tartary buckwheat flavone has the activity function of promoting apoptosis of the pancreatic cancer cells, and then the activity effect of resisting pancreatic cancer is achieved.

The invention relates to a traditional Chinese medicine composition for treating lymphoma and a preparation method and application thereof. The traditional Chinese medicine composition is prepared from the following medicines in parts by weight: 10-30 parts of spica prunellae, 3-18 parts of edible tulip, 9-30 parts of salvia chinensis, 9-30 parts of herba violae, 3-18 parts of semen impatientis, 25-35 parts of raw semen coicis, 9-30 parts of rhizoma sparganii, 9-30 parts of curcuma zedoary, 10-30 parts of cortex lycii radicis, 3-18 parts of herba patriniae, 3-18 parts of turtle shell, 3-18 parts of rhizoma anemarrhenae, 3-18 parts of pericarpium citri reticulatae, 3-18 parts of ginger processed pinellia, 5-30 parts of white poria cocos and 3-9 parts of liquorice. The traditional Chinese medicine composition further comprises the following raw material medicine in parts by weight: 0.05-0.1 part of realgar. The traditional Chinese medicine composition has the advantages that the traditional Chinese medicine composition can effectively inhibit proliferation and growth of lymphoma cells Raji cells and Jeko-1 cells, and time and concentration dependence is shown. In addition, the detoxification and tumor elimination formula can also up-regulate expression of pro-apoptotic protein of lymphoma cells and inhibit expression of anti-apoptotic protein of the lymphoma cells at the same time, so that obvious apoptotic bodies are formed, apoptosis of the lymphoma cells is effectively promoted, and the detoxification and tumor elimination formula is concentration-dependent.

The invention discloses application and a method of E199L protein in promoting cell apoptosis. The invention provides an application of E199L in promoting cell apoptosis, the E199L competitively destroys the interaction between anti-apoptosis proteins and BAK and / or BAX through the wide interaction between the E199L and the anti-apoptosis proteins such as BCL-XL, MCL-1, BCL-W and BCL-2A1, and finally induces cell apoptosis.

In the invention, polysaccharides are extracted from wolfberry black fruit, and the content of polysaccharides is determined by using anthrone-ethyl acetate-concentrated sulfuric acid solution. Crushing, soaking, heating, filtering, suction filtration and other treatments are performed on the fruit of Lycium barbarum to obtain a solution containing Lycium barbarum polysaccharide. The extracted Lycium barbarum polysaccharides were extracted with water, alcohol-precipitated, and suction-filtered, and the filter cake was dried in an oven. The polysaccharide powder was taken separately, dissolved after adding DMSO, stirred for 12 hours under a magnetic stirrer, added distilled water, and suction-filtered. The precipitate is washed successively with absolute ethanol, acetone and ether, and dried to obtain the refined Lycium ruthenicum polysaccharide; after the obtained refined Lycium ruthenicum polysaccharide is decolorized by macroporous resin and deproteinized by Sevage method, the black fruit Lycium barbarum polysaccharide. Refining with DMSO greatly increases the yield of polysaccharides. When the Lycium barbarum polysaccharides are applied to K562 cells, they can promote cell apoptosis by changing the expression of apoptotic proteins in the mitochondrial pathway, and have anti-leukemic tumor effects.

The invention relates to an application of a recombinant ganoderma lucidum immunoregulatory protein (rLZ-8) in preparation of medicines for treating chronic cardiac failure. According to the invention, a rat cardiac failure model is established by intraperitoneal injection of adriamycin amycin (ADR) to study the curative effect of rLZ-8 to chronic cardiac failure. Experimental research results show that rLZ-8 can remarkably improve the cardiac function of the rat cardiac failure model, reduce the rate of myocardial apoptosis, reduce expression of relevant apoptin in myocardial cells (caspase3 and caspase9) and increase the survival rate of rats with chronic heart failure.

The invention relates to the technical field of treatment of ocular tissue lesions, and particularly discloses application of ellagic acid in preparation of a medicine for relieving ocular tissue lesions, wherein the ellagic acid can regulate and control the rise of the expression level of LC3b / a protein and the reduction of the expression level of p62 protein in eyeball tissues of diabetic mice, improve autophagy disorder of diabetic ocular tissues, relieve diabetic mouse eye tissue pathological injury, inhibit eye tissue inflammation NLRP3 and IL-1beta protein expression, inhibit eye tissue apoptosis protein c-caspase1 expression, and inhibit mouse eye tissue pyroptosis protein GSDME, GSDME-N and GSDMD-N expression, so that GSDMD and GSDME mediated pyroptosis is inhibited, and an anti-inflammatory protection effect on cells is achieved. The ellagic acid provided by the invention can relieve pathological injury of eye tissues of diabetic mice and has a protective effect on retinas of the diabetic mice.

The invention discloses an apoptosis protein fusion type anti-HER-2 single chain antibody and its preparation method and application. The apoptotic protein is cytochrome C or DNA fragmentation factor 40, which can be conjugated with anti-HER-2 single-chain antibody to form DFF40-scFv fusion single-chain antibody, nCytc (tandem)-scFv fusion single-chain antibody. The apoptotic protein fusion anti-HER-2 single chain antibody is inserted into the upstream of the scFv by the cDNA sequence of the apoptotic protein and cloned into the expression vector to construct a recombinant plasmid, and the recombinant plasmid is transferred into cells to induce the expression of the apoptotic protein fusion anti-HER-2 single chain antibody, the preparation method is easy to construct and express, and the constructed apoptotic protein fusion anti-HER-2 single-chain antibody can specifically target malignant tumors with high expression of HER-2 and mediate apoptosis of cancer cells, and can be used to prepare targeted Drugs to treat cancers with high expression of HER‑2.

The invention discloses a preparation method of a compound PGHG in a medicine for treating parkinson's disease. The method comprises the following steps: performing ultrasonic extraction on Penthorumchinense Pursh. stem dry powder by using 70 percent of ethanol (1: 25), sequentially performing extraction by using petroleum ether and ethyl acetate to obtain extracting solutions; performing decompressing concentration and lyophilization on the extracting solutions to obtain Penthorum chinense Pursh. polyphenol fragments (PSE); separating the PSE through high-speed countercurrent chromatographyto obtain flow fractions A and B; further purifying the flow fraction A by adopting a preparative HPLC (High Performance Liquid Chromatography); manually collecting effluent liquid according to a chromatographic peak; performing decompressing concentration to obtain a monomer compound of which the purity is up to 99 percent; and the monomer compound is identified as PGHG through mass spectrometryand nuclear magnetic resonance spectroscopy. Due to the PSE and the PGHG, reduction of ATP level of 6-hydroxydopamine induced SH-SY5Y cells can be obviously suppressed, and the cell activity is improved. The PGHG can modulate and control expression of apoptosis protein and inflammatory protein through activating Nrf2 / HO-1 antioxidant pathway, and neuroprotection has an obvious effect on preventionand treatment of the parkinson's disease.

The invention belongs to the field of medicinal chemistry, and particularly relates to a marine natural product Chrysamide B and a derivative thereof. The marine natural product Chrysamide B comprisesstereoisomers or pharmaceutically acceptable salts, solvates and prodrugs of the marine natural product Chrysamide B, general formulas are shown in a formula (I), a formula (II) and a formula (III).The invention also provides preparation and application of the compound. The compound has an anti-cancer effect; the compound has good inhibitory activity on digestive system cancers, leukemia, livertumors, non-small cell lung cancers, cervical cancers, breast cancers and the like and has the effects of inducing tumor cell apoptosis, activating apoptosis protein expression, retarding cycle, inhibiting proliferation and the like and is a potential antitumor drug.